In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.

Published Date: 29 Jan 2024

Benefit from immune checkpoint inhibitor more than doubles when compared to observation.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

As compared to proton therapy, proton therapy is very effective in treating esophageal cancer.

2.

In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.

3.

Highly Successful Treatment of Lynch Syndrome Patients with PD-1 Inhibitors for Colorectal Cancer.

4.

Inadvertent lung cancer screening results are discussed in a new study.

5.

Q&A: When will individuals be able to receive customized cancer vaccines?


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot